EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
Source: EQS
Currently, Ac-225-based radiopharmaceuticals are under clinical investigation for various cancers, including prostate tumors, colorectal cancer, and leukemia. A substantial increase in the demand for Ac-225 is projected over the next decade, driven by its expanding clinical applications and the promising results seen in ongoing trials. Despite its therapeutic promise, sufficient quantities of Ac-225 remain scarce. "Eckert & Ziegler, in conjunction with UJF, has explored one of the most promising cyclotron-based production pathways for Ac-225," said Dr. The newly inaugurated laboratory will leverage cutting-edge technologies, including a customized production line provided by "Today's opening marks a significant achievement in our collaboration with Eckert & Ziegler," commented Prof. Ondřej Lebeda, Head of Actinium-225 has emerged as a highly promising agent in the targeted therapy of small tumors and metastases. Its high-energy cascade of alpha particles with short penetration depths allows for precise targeting of tumor cells, including difficult-to-reach micro metastases, while minimizing impact on surrounding healthy tissue. About Eckert & Ziegler Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives. About UJF Contact Eckert & Ziegler SE Robert-Rössle-Str. 10, 13125 Jan Schöpflin, Marketing / jan.schoepflin@ezag.de / karolin.riehle@ezag.de Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com
|
Language: | English |
Company: | Eckert & Ziegler SE |
Robert-Rössle-Str.10 | |
13125 |
|
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-0 |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, TecDax, |
Listed: | Regulated Market in |
EQS News ID: | 1928009 |
End of News |
|
1928009 19.06.2024 CET/CEST